Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations.
DZD9008 (sunvozertinib) in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease has progressed on/after platinum-based chemotherapy has met its the primary end point of confirmed objective response (ORR) at 59.8%, according to Dizal Pharmaceutical.1
The response rate for patients with baseline brain metastasis was 48.4% and clinical activities were observed across a broad range of EGFR exon 20 insertion mutation subtypes, regardless of mutation positions. Additionally, the safety profile of DZD9008 was benign with mild adverse events (AEs).
DZD9008 is a rationally designed, oral, potent EGFR exon 20 insertion inhibitor, with wild-type EGFR selectivity. Previously, DZD9008 was granted a breakthrough therapy designation by the FDA in January 2022. Read more.